Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

NCT03853044 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT03853044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03853044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
December 29, 2018
Completion date
December 31, 2022
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma